(Total Views: 486)
Posted On: 08/17/2020 5:50:20 PM
Post# of 149265
Re: chuckles759 #50169
Saw your post, and think it was/is an excellent point. I noticed that NP repeated the statement that it is very hard to show mortality benefit.
The blog post/article you linked was from March 2020, and it didn't discuss any of the Covid trials (dexamethasone and itolizumab) out after that. I would guess that the dexamethasone study was solid (N=1500) but not the itolizumab one (N=30).
The blog author introduced an interesting concept (new to me) of the fragility index:
https://clincalc.com/Stats/FragilityIndex.aspx
I'm pretty sure the author would suggest that the itolizumab study was too small, and thus very "fragile" to a single subject or two dying or not.
I didn't calculate Fragility Index for itolizumab study but it could easily be done and compared if someone was bored enough to look.
The blog post/article you linked was from March 2020, and it didn't discuss any of the Covid trials (dexamethasone and itolizumab) out after that. I would guess that the dexamethasone study was solid (N=1500) but not the itolizumab one (N=30).
The blog author introduced an interesting concept (new to me) of the fragility index:
https://clincalc.com/Stats/FragilityIndex.aspx
I'm pretty sure the author would suggest that the itolizumab study was too small, and thus very "fragile" to a single subject or two dying or not.
I didn't calculate Fragility Index for itolizumab study but it could easily be done and compared if someone was bored enough to look.
(0)
(0)Scroll down for more posts ▼
